Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Hepatocellular carcinoma (HCC) is associated with high malignancy rates. Recently, a known deacetylase SIRT1 is discovered in HCC, while its presence is positively correlated with malignancy and metastasis. N<sup>6</sup>‐methyladenosine (m<sup>6</sup>A) is the most prominent modification but the exact mechanisms on how SIRT1 regulates m<sup>6</sup>A modification to induce hepatocarcinogenesis remain unclear. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>Here we demonstrate that SIRT1 exerts oncogenic role by downregulating fat mass and obesity‐associated protein (FTO), which is an m<sup>6</sup>A demethylase. A crucial component of small ubiquitin‐related modifiers (SUMOs) E3 ligase, RANBP2, is activated by SIRT1 and it is indispensable for FTO SUMOylation at Lysine (K)‐216 site that promotes FTO degradation. Moreover, Guanine nucleotide‐binding protein G (o) subunit alpha (GNAO1) is firstly identified as m<sup>6</sup>A downstream targets of FTO and tumor suppressor in HCC, and depletion of FTO by SIRT1 improves m<sup>6</sup>A<sup>+</sup> GNAO1 and downregulates its mRNA expression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>We demonstrate an important mechanism whereby SIRT1 destabilizes FTO, steering the m<sup>6</sup>A<sup>+</sup> of downstream molecules and subsequent mRNA expression in HCC tumorigenesis. Our findings uncover a novel target of SIRT1 for therapeutic agents to treat HCC. </p></section>

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism of action of SIRT1 in the occurrence and development of hepatocellular carcinoma (HCC), especially how SIRT1 regulates m6A RNA modification by inducing RANBP2 - dependent FTO SUMOylation. Specifically, the study focused on the following aspects: 1. **The relationship between SIRT1 and HCC**: First, the study confirmed that the expression level of SIRT1 in HCC tissues was significantly higher than that in normal tissues, and the expression of SIRT1 was closely related to tumor grade, T classification, and N classification, indicating that SIRT1 may play an important role in promoting cancer in HCC. 2. **The influence of SIRT1 on FTO**: The study found that SIRT1 could promote the development of HCC by down - regulating the expression of FTO. FTO is an m6A demethylase, and the decrease in its expression will lead to an increase in m6A modification, which in turn affects the expression of downstream genes. The experimental results showed that over - expression of SIRT1 could significantly reduce the protein level of FTO, and knockdown of FTO could partially reverse the cancer - promoting effect of SIRT1. 3. **The role of RANBP2 in SIRT1 - regulated FTO**: Further research revealed that RANBP2, as an E3 SUMO ligase, plays a key role in the process of SIRT1 - regulated FTO. SIRT1 promotes the SUMOylation of FTO at Lysine - 216 by activating RANBP2, resulting in the instability and degradation of FTO. 4. **SIRT1 affects the m6A modification of GNAO1 through FTO**: Finally, the study found that SIRT1 increased the m6A modification level of the HCC tumor - suppressor gene GNAO1 by down - regulating FTO, which in turn reduced the mRNA expression of GNAO1. This indicates that SIRT1 may participate in the occurrence and development of HCC by regulating m6A modification and affecting the expression of specific genes such as GNAO1. In summary, this paper aims to explore the specific mechanism of action of SIRT1 in HCC, especially by regulating m6A RNA modification through RANBP2 - dependent FTO SUMOylation, thereby affecting the expression of downstream genes such as GNAO1, providing a new potential target for the treatment of HCC.

SIRT1 Regulates N 6 ‐Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2‐Dependent FTO SUMOylation